|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-3-26
|
|
pubmed:abstractText |
Beginning with the weakly active lead structure 1, a new series of hPPAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. Further manipulation afforded benzofurans 6 and 7. Compound 7 was of comparable potency as a glucose and triglyceride lowering agent in insulin resistant rodents to BRL 49653.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BergerGregory DGD,
pubmed-author:BergerJoelJ,
pubmed-author:DoebberThomasT,
pubmed-author:MacNaulKarenK,
pubmed-author:MollerDavid EDE,
pubmed-author:MosleyRalphR,
pubmed-author:SahooSoumya PSP,
pubmed-author:SantiniConradC,
pubmed-author:TolmanRichard LRL,
pubmed-author:VosJ JJJ,
pubmed-author:WuMargaretM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
7
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1277-80
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12657263-Animals,
pubmed-meshheading:12657263-Blood Glucose,
pubmed-meshheading:12657263-Dose-Response Relationship, Drug,
pubmed-meshheading:12657263-Drug Design,
pubmed-meshheading:12657263-Hypoglycemic Agents,
pubmed-meshheading:12657263-Insulin Resistance,
pubmed-meshheading:12657263-Male,
pubmed-meshheading:12657263-Mice,
pubmed-meshheading:12657263-Phenylacetates,
pubmed-meshheading:12657263-Rats,
pubmed-meshheading:12657263-Rats, Zucker,
pubmed-meshheading:12657263-Receptors, Cytoplasmic and Nuclear,
pubmed-meshheading:12657263-Thiazoles,
pubmed-meshheading:12657263-Thiazolidinediones,
pubmed-meshheading:12657263-Transcription Factors,
pubmed-meshheading:12657263-Triglycerides
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phenylacetic acid derivatives as hPPAR agonists.
|
|
pubmed:affiliation |
Department of Basic Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. conrad_santini@merck.com
|
|
pubmed:publicationType |
Journal Article
|
